Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Rhea-AI Summary
Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 A.M. ET. CEO Chip Clark will discuss the company’s work in developing next-generation neoantigen immunotherapies, focusing on their proprietary ATLAS™ platform. A live webcast of the presentation will be available on Genocea's investor relations site, with a replay accessible for 90 days.
Genocea aims to create life-changing immunotherapies for cancer by identifying and targeting tumor antigens.
Positive
- None.
Negative
- None.
News Market Reaction – GNCA
In the trading session that priced this news, GNCA gained 3.85%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET.
A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation.
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
